PRME

Prime Medicine, Inc.

A biotechnology company developing "Prime Editing," a gene-editing technology that acts like a molecular word processor, able to search for and rewrite faulty DNA without cutting both strands like earlier CRISPR "scissors." Founded in 2019, Prime Medicine aims to turn this science into one-time treatments for serious inherited diseases, and its lead therapy targets chronic granulomatous disease, a rare immune disorder. The company takes its name from the Prime Editing technology it was built around.

CUSIP: 74168J101HealthcareUS2 holders

Ownership Activity Financials Filings

PRME

PRME

Results of Operations and Financial Condition

Other Events

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Results of Operations and Financial Condition

Regulation FD Disclosure

Results of Operations and Financial Condition